Publications by authors named "James Gow"

Claim this Profile
A
An atypical manifestation of Giant cell arteritis (GCA): constitutional symptoms & lingual ulcer in a 78-Year-Old male with negative temporal artery biopsies.
James Gow, David Roofeh

BMC Rheumatol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of Visual Function with Cotoretigene Toliparvovec in X-Linked Retinitis Pigmentosa in the Randomized XIRIUS Phase 2/3 Study.
Byron L Lam, Mark E Pennesi, Christine N Kay, Sushil Panda, James A Gow

Ophthalmology· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An Open-Label Phase II Study Assessing the Safety of Bilateral, Sequential Administration of Retinal Gene Therapy in Participants with Choroideremia: The GEMINI Study.
Robert E MacLaren, Isabelle Audo, M Dominik Fischer, Rachel M Huckfeldt, Byron L Lam, James A Gow

Hum Gene Ther· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
X
XOLARIS: A 24-Month, Prospective, Natural History Study of 201 Participants with -Associated X-Linked Retinitis Pigmentosa.
Robert E MacLaren, Jacque L Duncan, M Dominik Fischer, Byron L Lam, Isabelle Meunier, James A Gow

Ophthalmol Sci· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Prospective, Observational, Non-interventional Clinical Study of Participants With Choroideremia: The NIGHT Study.
Robert E Maclaren, Byron L Lam, M Dominik Fischer, Frank G Holz, Mark E Pennesi, James A Gow

Am J Ophthalmol· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Subretinal timrepigene emparvovec in adult men with choroideremia: a randomized phase 3 trial.
Robert E MacLaren, M Dominik Fischer, James A Gow, Byron L Lam, Eeva-Marja K Sankila

Nat Med· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Changes in Retinal Sensitivity Associated With Cotoretigene Toliparvovec in X-Linked Retinitis Pigmentosa With RPGR Gene Variations.
Lenore von Krusenstiern, Jiajun Liu, Eileen Liao, James A Gow, Guo Chen

JAMA Ophthalmol· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ACAT1/SOAT1 Blockade Suppresses LPS-Mediated Neuroinflammation by Modulating the Fate of Toll-like Receptor 4 in Microglia.
Haibo Li, Thao N Huynh, Michael Tran Duong, James G Gow, Catherine C Y Chang

Int J Mol Sci· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Blocking cholesterol storage to treat Alzheimer's disease.
Ta Yuan Chang, Catherine C Y Chang, Taylor C Harned, Adrianna L De La Torre, Junghoon Lee, James G Gow

Explor Neuroprotective Ther· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Myeloid cell dynamics in bleomycin-induced pulmonary injury in mice; effects of anti-TNFα antibody.
Alessandro Venosa, James G Gow, Sheryse Taylor, Thea N Golden, Alexa Murray, Andrew J Gow

Toxicol Appl Pharmacol· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fatty acid nitroalkenes inhibit the inflammatory response to bleomycin-mediated lung injury.
Melissa L Wilkinson, Elena Abramova, Changjiang Guo, James G Gow, Alexa Murray, Andrew J Gow

Toxicol Appl Pharmacol· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nitric Oxide Regulates Macrophage Fungicidal Activity -nitrosylation of Dectin-1.
James Gow, Yujie Yang, Mohan Govindraj, Changjiang Guo

Appl In Vitro Toxicol· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Participation in patient support forums may put rare disease patient data at risk of re-identification.
James Gow, Colin Moffatt, Jamie Blackport

Orphanet J Rare Dis· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Regulation of Nitrogen Mustard-Induced Lung Macrophage Activation by Valproic Acid, a Histone Deacetylase Inhibitor.
Alessandro Venosa, James G Gow, LeRoy Hall, Rama Malaviya, Andrew J Gow

Toxicol Sci· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prospective Evaluation of Outcomes in Patients Undergoing Treatment for Myopia Using the WaveLight Refractive Suite.
Arthur Cummings, Daniel Durrie, Michael Gordon, Ravaughn Williams, James A Gow

J Refract Surg· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bromfenac ophthalmic solution 0.07% dosed once daily for cataract surgery: results of 2 randomized controlled trials.
Thomas R Walters, Damien F Goldberg, James H Peace, James A Gow,

Ophthalmology· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of bepotastine besilate ophthalmic solution 1.5% for seasonal allergic conjunctivitis: a randomized, placebo-controlled, natural exposure, clinical trial.
Warner W Carr, Anjuli S Nayak, Paul H Ratner, James A Gow, Timothy R McNamara

Allergy Asthma Proc· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Integrated phase III trials of bepotastine besilate ophthalmic solution 1.5% for ocular itching associated with allergic conjunctivitis.
Edward J Meier, Gail L Torkildsen, James A Gow, Timothy R McNamara, Paul J Gomes

Allergy Asthma Proc· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of bromfenac ophthalmic solution (Bromday) dosed once daily for postoperative ocular inflammation and pain.
Bonnie A Henderson, Johnny L Gayton, Simon P Chandler, James A Gow, Sharon M Klier

Ophthalmology· November 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Once daily dosing of bromfenac ophthalmic solution 0.09% for postoperative ocular inflammation and pain.
Steven M Silverstein, Melissa G Cable, Ehsan Sadri, James H Peace, Raymond Fong, James A Gow

Curr Med Res Opin· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prolonged effectiveness of bepotastine besilate ophthalmic solution for the treatment of ocular symptoms of allergic conjunctivitis.
Jon I Williams, Kathryn S Kennedy, James A Gow, Gail L Torkildsen, Mark B Abelson

J Ocul Pharmacol Ther· August 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Non-clinical pharmacology, pharmacokinetics, and safety findings for the antihistamine bepotastine besilate.
Jon I Williams, James A Gow, Sharon M Klier, Shannon L McCue, Anne Marie F Salapatek

Curr Med Res Opin· October 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multicenter clinical evaluation of bepotastine besilate ophthalmic solutions 1.0% and 1.5% to treat allergic conjunctivitis.
Thomas T Macejko, Mark T Bergmann, Jon I Williams, James A Gow, Paul J Gomes

Am J Ophthalmol· July 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bepotastine besilate ophthalmic solution for the relief of nonocular symptoms provoked by conjunctival allergen challenge.
Gail L Torkildsen, Jon I Williams, James A Gow, Paul J Gomes, Mark B Abelson

Ann Allergy Asthma Immunol· July 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Time to onset and duration of action of the antihistamine bepotastine besilate ophthalmic solutions 1.0% and 1.5% in allergic conjunctivitis: a phase III, single-center, prospective, randomized, double-masked, placebo-controlled, conjunctival allergen challenge assessment in adults and children.
Mark B Abelson, Gail L Torkildsen, Jon I Williams, James A Gow, Paul J Gomes

Clin Ther· September 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis